Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Poniatowa – page 12

827 clinical trials in Poniatowa, Poland across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Poniatowa at a glance
827
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

827 trials in Poniatowa

Open in trial search

Cenegermin Eye Drops for Persistent Corneal Epithelial Defect in Patients with Persistent Corneal Epithelial Defect

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cenegermin
  • Sponsor:Dompe' Farmaceutici S.p.A.

AZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:AZD0120
  • Sponsor:AstraZeneca AB

Tulisokibart for Psoriatic Arthritis in Adults

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tulisokibart
  • Sponsor:Merck Sharp & Dohme LLC

A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

A study to evaluate the effectiveness of a drug combination in reducing respiratory tract infections in children aged 3 to 12 years.

Registered drug
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Placebo
  • Sponsor:Lallemand Pharma Europe filial af Lallemand Pharma AG Schweiz

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:BeOne Medicines I GmbH

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Obesity+1

Recruiting

A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Psoriasis

Recruiting

A study to evaluate the effectiveness and safety of zasocitinib in children and adolescents with moderate-to-severe plaque psoriasis

Investigational
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Zasocitinib
  • Sponsor:Takeda Development Center Americas Inc.

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Amgen Inc.

A study to evaluate the efficacy and safety of lesigercept in adults with chronic spontaneous urticaria who do not have enough relief from antihistamines

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Lesigercept
  • Sponsor:Yuhan Corp.

A study to investigate the safety and effects of ceralasertib, tremelimumab, and durvalumab in adults with various solid tumors

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Durvalumab
  • Sponsor:AstraZeneca AB

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Poniatowa

What the registry says about research in the country

01 Cardiovascular Research

Innovative clinical trials focusing on hyperlipidemia management, specifically targeting patients at high and very high cardiovascular risk. The research evaluates the effectiveness of rosuvastatin treatments and combination therapies in achieving optimal LDL-C reduction.

  • Lipid Management
  • Cardiovascular Risk Prevention
  • Combination Therapy Assessment

These studies aim to establish more effective treatment protocols for patients requiring intensive lipid-lowering therapy.

02 Rheumatology Studies

Comprehensive research evaluating biosimilar treatments for rheumatoid arthritis. The trials compare the efficacy of new biosimilar options with established treatments, focusing on patients with moderate to severe disease conditions.

  • Biosimilar Development
  • Treatment Efficacy Assessment
  • Immunogenicity Studies

This research aims to expand treatment options while maintaining high efficacy standards in rheumatoid arthritis management.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.